236 related articles for article (PubMed ID: 28230455)
1. Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center.
Yang S; Britt RB; Hashem MG; Brown JN
J Manag Care Spec Pharm; 2017 Mar; 23(3):364-369. PubMed ID: 28230455
[TBL] [Abstract][Full Text] [Related]
2. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
[TBL] [Abstract][Full Text] [Related]
3. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
5. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.
Benhammou JN; Dong TS; May FP; Kawamoto J; Dixit R; Jackson S; Dixit V; Bhattacharya D; Han SB; Pisegna JR
Pharmacol Res Perspect; 2018 Apr; 6(2):e00379. PubMed ID: 29484189
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
7. Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4.
Bach TA; Zaiken K
J Manag Care Spec Pharm; 2016 Dec; 22(12):1437-1445. PubMed ID: 27882839
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
9. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
10. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
[No Abstract] [Full Text] [Related]
11. Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital.
Tran AN; Sachdev R; Fricker ZP; Leber M; Zahorian T; Shah B; Nunes DP; Long MT
Dig Dis Sci; 2018 Dec; 63(12):3241-3249. PubMed ID: 30078116
[TBL] [Abstract][Full Text] [Related]
12. Overview of Comprehensive Hepatitis C Virus Medication Management in a State Medicaid Program.
Lavitas P; Tesell M; Hydery T; Greenwood BC; Price M; Lenz K; Jeffrey P
J Manag Care Spec Pharm; 2016 Oct; 22(10):1161-6. PubMed ID: 27668564
[TBL] [Abstract][Full Text] [Related]
13. Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center.
Downes JM; Donovan A; McAdam-Marx C
J Am Pharm Assoc (2003); 2022; 62(5):1596-1605. PubMed ID: 35595639
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Direct-Acting Antiviral Treatment Selection, Treatment Failure, and Use of Drug-Drug Interactions in a State Medicaid Program.
Keast SL; Holderread B; Cothran T; Skrepnek GH
J Manag Care Spec Pharm; 2019 Nov; 25(11):1261-1267. PubMed ID: 31663456
[TBL] [Abstract][Full Text] [Related]
15. Applicability of a new specialty pharmacy-reported measure describing completion of therapy for hepatitis C.
Bolduc C; McCall K; Stickney K; Gelinas A; Levesque E
J Manag Care Spec Pharm; 2021 Feb; 27(2):263-267. PubMed ID: 33506724
[No Abstract] [Full Text] [Related]
16. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
17. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Martin MT; Deming P
Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
[TBL] [Abstract][Full Text] [Related]
18. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
[TBL] [Abstract][Full Text] [Related]
19. Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs.
Belperio PS; Chartier M; Ross DB; Alaigh P; Shulkin D
Ann Intern Med; 2017 Oct; 167(7):499-504. PubMed ID: 28973196
[TBL] [Abstract][Full Text] [Related]
20. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
